Description
Anti-G-Protein-coupled Receptor 49 Antibody, Non-Fucosylated (BioBet-1178ZP) is a humanized monoclonal IgG antibody against G-Protein-coupled Receptor 49. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced G-Protein-coupled Receptor 49 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
LGR5
Full Name
leucine-rich repeat containing G protein-coupled receptor 5
Alternative Names
LGR5; leucine-rich repeat containing G protein-coupled receptor 5; FEX; HG38; GPR49; GPR67; GRP49; leucine-rich repeat-containing G-protein coupled receptor 5; G-protein coupled receptor 49; G-protein coupled receptor 67; G-protein coupled receptor HG38; orphan G protein-coupled receptor HG38; leucine-rich repeat-containing G protein-coupled receptor 5
Gene ID
8549
Cellular Localization
Golgi apparatus, Plasma membrane
Involvement in Disease
Diseases associated with LGR5 include Colon Adenoma and Ankyloglossia With Or Without Tooth Anomalies.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
The receptor for r-spondins enhances the typical Wnt signaling pathway and serves as a stem cell marker for intestinal epithelium and hair follicles. After binding to r-spondins (RSPO1, rspo2, Rspo3 or rspo4), it binds to phosphorylated LRP6 and curl receptors activated by extracellular Wnt receptors, triggering a typical Wnt signaling pathway to increase the expression of target genes. Unlike the classical G-protein-coupled receptor, it does not activate heterotrimeric G-protein to transmit signals. It is involved in the development and / or maintenance of adult intestinal stem cells during late embryonic development.
Field of research
Cancer antibody; Developmental Biology antibody; Signaling Transduction antibody
Post-translational modifications
1.Glycosylation at Asn63, Asn77, Asn208, Asn500, and Asn792 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1178ZP
Description
BNC101 is a humanized monoclonal antibody targeting LGR5, that has demonstrated functional activity against Cancer Stem Cells (CSCs) from primary colorectal cancer (CRC) patient samples. In preclinical studies, BNC101 significantly reduces CSC frequency in vivo and prevents tumour re-growth in long term studies. BNC101 also increases survival and inhibits weight loss in a cachexic CRC tumour model. To date BNC101 has shown no evidence of toxicity in preliminary safety analyses.
Antibody Indication
Cancer
